Evidence map›Paper›PMID 27001666›Full record

ArticleBMC bioinformatics2016

Leveraging protein quaternary structure to identify oncogenic driver mutations.

Gregory A Ryslik, Yuwei Cheng, Yorgo Modis, Hongyu Zhao

Abstract read
In one paragraph

Article in BMC bioinformatics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Computational methods for detecting cancer hotspots.Computational and structural biotechnology journal · 2020
    Review
  3. Leveraging protein dynamics to identify cancer mutational hotspots using 3D structures.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  4. Functional characterization of 3D protein structures informed by human genetic diversity.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gregory A RyslikDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA. gregory.ryslik@yale.edu.
Yuwei ChengProgram of Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.
Yorgo ModisDepartment of Medicine, University of Cambridge, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK.
Hongyu ZhaoDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of IrinP01CA154295 · NCI · YALE UNIVERSITY · PI CHENG, YUNG-CHI · 2011 to 2016
$6.4M
STATISTICAL METHODS TO MAP GENES FOR COMPLEX TRAITSR01GM059507 · NIGMS · YALE UNIVERSITY · PI ZHAO, HONGYU · 1999 to 2013
$3.6M
The structural basis of nucleic acid recognition by Toll-like receptorsR01GM102869 · NIGMS · YALE UNIVERSITY · PI MODIS, YORGO · 2012 to 2015
$1.1M
NCATS NIH HHS UL1 TR001863NCI NIH HHS CA154295NCI NIH HHS P01 CA154295NCI NIH HHS P30 CA016359NIGMS NIH HHS GM102869NIGMS NIH HHS GM59507NIGMS NIH HHS R01 GM059507NIGMS NIH HHS R01 GM102869Wellcome Trust 101908Wellcome Trust 101908/Z/13/Z
6 · The paper itself

Abstract

backgroundIdentifying key "driver" mutations which are responsible for tumorigenesis is critical in the development of new oncology drugs. Due to multiple pharmacological successes in treating cancers that are caused by such driver mutations, a large body of methods have been developed to differentiate these mutations from the benign "passenger" mutations which occur in the tumor but do not further progress the disease. Under the hypothesis that driver mutations tend to cluster in key regions of the protein, the development of algorithms that identify these clusters has become a critical area of research.

resultsWe have developed a novel methodology, QuartPAC (Quaternary Protein Amino acid Clustering), that identifies non-random mutational clustering while utilizing the protein quaternary structure in 3D space. By integrating the spatial information in the Protein Data Bank (PDB) and the mutational data in the Catalogue of Somatic Mutations in Cancer (COSMIC), QuartPAC is able to identify clusters which are otherwise missed in a variety of proteins. The R package is available on Bioconductor at: http://bioconductor.jp/packages/3.1/bioc/html/QuartPAC.html .

conclusionQuartPAC provides a unique tool to identify mutational clustering while accounting for the complete folded protein quaternary structure.

Indexed as

User-Computer InterfaceAlgorithmsCluster AnalysisDatabases, ProteinHumansInternetMutationNeoplasmsProteinsProtein Structure, QuaternaryProteins

Identifiers

PMID27001666
PMCPMC4802602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.